Neurotrope Inc (NTRP) 0.4500 $NTRP
Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead Drug Candidate, Bryostatin-1, for the Treatment of Advanced Alzheimer's Disease
PR Newswire - Mon Aug 15, 7:30AM CDT
Neurotrope, Inc. (OTCBB:NTRP) today announced that its wholly owned subsidiary, Neurotrope BioScience, Inc., has submitted to the Food and Drug Administration (FDA) an amended protocol for its Phase 2 clinical trial of lead candidate bryostatin-1 for the treatment of advanced Alzheimer's disease. As planned in the original protocol, the primary efficacy outcome will occur at Week 13, and does not change with this amendment. The primary efficacy endpoint is based on the Severe Impairment Battery scale, a well-validated assessment used extensively in severe Alzheimer's disease drug trials. Secondary efficacy endpoints include Activities of Daily Living, Neuropsychiatric Inventory and Mini-Mental State Exam. As a result of this amendment, the Company expects to report top line data late in the first quarter or early in the second quarter of 2017.
Neurotrope Announces Changes to the Board of Directors and Management
PR Newswire - Fri Aug 05, 7:30AM CDT
Neurotrope, Inc. (OTCBB: NTRP) (the "Company"
, focused on developing drugs to treat neurological diseases including Alzheimer's disease, today announced it has reached a settlement agreement with Iroquois Master Fund Ltd. and certain of its affiliates (collectively "Iroquois", with regard to a proposed consent solicitation by Iroquois.
Neurotrope announces that a new study published in the Journal of Biological Chemistry shows that Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
PR Newswire - Thu Jun 23, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that a study published in the Journal of Biological Chemistry shows that its lead Alzheimer's drug, Bryostatin, licensed from the Blanchette Rockefeller Neurosciences Institute (BRNI), increases the levels of the synaptic scaffolding protein PSD-95, and induces the movement of phosphorylated PSD-95 to the neuronal membranes. The study, conducted within the BRNI basic research programs, showed that Bryostatin induced activation of PKC epsilon increased synaptic number, pre-synaptic vesicle density, and clusters of PSD-95. It is known that either AB or tau, both toxic proteins in Alzheimer's disease brains, can induce reduction of PSD-95 in excitatory synapses in hippocampus. Furthermore, this PSD-95 reduction continues to occur as the Alzheimer's pathologies advance. A Phase 2b clinical trial funded by Neurotrope Bioscience, Inc., Neurotrope, Inc.'s wholly-owned subsidiary, is underway to test the efficacy of Bryostatin for the treatment of the causes and progression of Alzheimer's disease.
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
PR Newswire - Tue Jun 21, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP): today announced that Paula T. Trzepacz, M.D., has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President and Chief Medical Officer.
Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease
PR Newswire - Mon Jun 13, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP): Dr. Daniel Alkon, Chief Scientific Officer of Neurotrope, discussed "Modulation of PKC Epsilon as a Therapeutic Strategy" as a potential treatment for both Fragile X mental retardation and Alzheimer's disease at the Autism-Related Disorders Gordon Conference.
Neurotrope Enters Into Research Collaboration With the International Rett Syndrome Foundation / Rettsyndrome.org
PR Newswire - Thu May 19, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer's disease (AD), is pleased to announce that it has entered into a research collaboration with the International Rett Syndrome Foundation, DBA: Rettsyndrome.org, to explore the potential of Bryostatin for the treatment of Rett syndrome.
Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model
PR Newswire - Tue Mar 08, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced that its lead Alzheimer's drug Bryostatin improved disease symptoms and restored normal synaptic networks in a young transgenic animal model of Fragile X Syndrome (FXS), a common genetic cause of mental retardation and autism. The study led by scientists at the Blanchette Rockefeller Neuroscience Institute (BRNI) demonstrated that chronic treatment with bryostatin-1 rescues young fragile X mice (corresponding to 15 - 16 year old children) from the disorder phenotypes, including reversal of most FXS abnormalities of 1) hippocampal brain-derived neurotrophic factor (BDNF) expression, 2) the synaptic anchoring protein, PSD-95, levels, 3) transformation of immature dendritic synapses to fully mature, developed synapses, 4) sub-cellular densities of the presynaptic and postsynaptic membranes, and 5) spatial learning and memory. These results were long lasting and confirmed by electron microscopy. While other attempts at Fragile X therapeutics have focused on reduced mGluR5 receptor levels, the Bryostatin efficacy for treating Fragile X did not require changes of mGluR5 and were even more dramatic than those of a late-onset treatment in adult Fragile X mice. As a result of the mutation of the FMR1 gene, the Fragile X mental retardation protein (FMRP) is not produced. It is known that this protein is abundant in the neurons of the hippocampus and cerebellum of non-affected individuals, but it is not yet fully understood why the absence of FMRP results in the phenotype of Fragile X. We have found that chronic activation of PKC in the hippocampus by Bryostatin can rescue synapses and spatial cognition, as well as other FXS phenotypes. This rescue in Fragile X mice is remarkably similar to the rescue of synapses, spatial cognition, and other Alzheimer's disease (AD) phenotypes in AD transgenic mice. The new Fragile X study in late brain development is entitled "Rescue of Synaptic Phenotypes and Special Memory in Young Fragile X Mice," was authored by Miao-Kun Sun, Jarin Hongpaisan, and Dr. Daniel L. Alkon, and is published, in the Fast Forward edition of the Journal of Pharmacology and Experimental Therapeutics, dated March 3, 2016.
Neurotrope CSO to Participate in Alzheimer's Panel at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 04, 10:19AM CST
Neurotrope, Inc. (NTRP) today announced that its Chief Scientific Officer, Dr. Daniel Alkon, has been invited to present on a panel focused on new directions and progress of Alzheimer's disease research at the 18 Annual BIO CEO & Investor Conference, being held February 8-9, 2016 at the Waldorf Astoria Hotel in New York, New York.
Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer's Disease
GlobeNewswire - Wed Feb 03, 7:40AM CST
Neurotrope, Inc. (OTCBB:NTRP) today announced that it has held an Investigators Meeting in conjunction with its recently initiated Phase 2b trial for lead compound, Bryostatin-1 for the treatment of Alzheimer's disease. The meeting, held January 28-29, 2016 in Orlando, Florida, brought together more than 150 healthcare clinical professionals from 30 sites across the United States to discuss the goals for the study, in addition to providing the in-depth training necessary for the trial.
Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer's Disease
GlobeNewswire - Thu Jan 07, 7:30AM CST
Neurotrope, Inc. (OTCBB:NTRP) today announced the initiation of a Phase 2b clinical trial of lead candidate Bryostatin 1 for the treatment of Alzheimer's Disease.
Neurotrope, Inc. Announces $15.3 million Private Placement
PR Newswire - Mon Nov 16, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced that it has entered into definitive agreements to sell its securities in a private placement. The securities purchase agreement provides for the sale of units to investors for $0.60 per unit with each unit consisting of one one-hundredth share of Series B Preferred Stock convertible into one share of common stock and one of each of the following warrants:
Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease
PR Newswire - Wed Jun 24, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its operating wholly-owned subsidiary ("Neurotrope", will conduct a preclinical study, in collaboration with a leading research institution, to examine the effect of bryostatin in Niemann-Pick type C (NPC) mice. The study is being funded by several family foundations under the auspices of Support Of Accelerated Research for NPC Disease ("SOAR-NPC".
Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C
PR Newswire - Fri Jun 12, 7:30AM CDT
Neurotrope Bioscience, Inc. (Neurotrope or the Company), the operating subsidiary of Neurotrope, Inc. (OTCQB: NTRP) today announced the Company will present the findings of in vitro studies of bryostatin's effects on Niemann Pick Type C1 cells (NPC1 cells) at the annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C research to be held on June 11 -13, 2015 at the University of Notre Dame. The Company's presentation will take place on Friday, June 12, at 2:30 pm Eastern time.
Neurotrope Joins National Organization for Rare Disorders (NORD) Corporate Council
PR Newswire - Thu Apr 23, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that, based upon its work in orphan drug indications, it has been invited to join the National Organization for Rare Disorders (NORD) as a member of the NORD Corporate Council. NORD is a leading independent, non-profit organization committed to the identification, treatment, and cure of rare disorders.
Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research
PR Newswire - Mon Apr 20, 7:35AM CDT
In the search for neuroscience drug discovery treatments, Alzheimer's disease and specifically autism drug candidates, a few viable therapeutic approaches have come from research on neurological conditions such as fragile X syndrome. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), CytRx Corporation (NASDAQ: CYTR), Trovagene, Inc., (NASDAQ: TROV), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Abbot Laboratories (NYSE: ABT) & Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).
ABT: 45.15 (+0.11), LXRX: 16.24 (+0.29), TROV: 5.71 (+0.10), CYTR: 0.58 (+0.01), BMY: 60.03 (-0.60), ARNA: 1.71 (+0.04)
Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies
PR Newswire - Mon Apr 20, 6:55AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that eurotrope BioScience, Inc., its wholly-owned operating subsidiary, has received a grant from the FRAXA Research Foundation, Inc. ("FRAXA" to fund a pre-clinical Fragile X Syndrome ("FXS" behavior study for its lead proprietary drug candidate, bryostatin, at FRAXA's purpose built laboratory located at the University of Chile in Santiago, Chile.
Leading Biotech Companies Seek Biologic Treatments for Rare Diseases Utilizing Viable Therapeutic Approach - Company Receives FDA Orphan Drug Designation for Bryostatin
PR Newswire - Thu Apr 09, 7:35AM CDT
According to a recent article published on the Wall Street Journal, the debate over prescription drug pricing has grown increasingly contentious, particularly as drug makers issue more new medicines with high price tags. But despite the tumult, the cost for orphan drugs - medicines that are designated by the FDA to treat a rare disease and may cost as much as $400,000 annually - is apparently not fazing some insurers. Billions of dollars a year are being earmarked for new clinical studies and trials for the treatment of neurodevelopmental disorders as leading biotech companies race to identify treatments for genetic, cognitive, and neural levels for autism disorders. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), Alkermes plc (NASDAQ: ALKS), Regulus Therapeutics Inc. (NASDAQ: RGLS), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Gilead Sciences Inc. (NASDAQ: GILD) and Abbot Laboratories (NYSE: ABT).
ABT: 45.15 (+0.11), INO: 8.88 (-0.07), GILD: 79.65 (-0.01), RGLS: 3.64 (+0.09), ALKS: 48.03 (+1.36)
Research & Clinical Trials for Prevention of Neurodegeneration Search for Viable Therapeutic Approach for the Treatment of Severe Alzheimer's Disease
PR Newswire - Mon Apr 06, 7:35AM CDT
The latest medical research and trials aimed to identify prevention of illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), Capnia, Inc. (NASDAQ: CAPN), Arena Pharmaceuticals, Inc., (NASDAQ: ARNA), Orexigen Therapeutics, Inc., (NASDAQ: OREX) & Inovio Pharmaceuticals, Inc., (NASDAQ: INO).
INO: 8.88 (-0.07), OREX: 4.34 (+0.16), CAPNU: (), ARNA: 1.71 (+0.04), CAPN: 0.90 (-0.05)
Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead Drug Candidate, Bryostatin-1, for the Treatment of Advanced Alzheimer's Disease
PR Newswire - Mon Aug 15, 7:30AM CDT
Neurotrope, Inc. (OTCBB:NTRP) today announced that its wholly owned subsidiary, Neurotrope BioScience, Inc., has submitted to the Food and Drug Administration (FDA) an amended protocol for its Phase 2 clinical trial of lead candidate bryostatin-1 for the treatment of advanced Alzheimer's disease. As planned in the original protocol, the primary efficacy outcome will occur at Week 13, and does not change with this amendment. The primary efficacy endpoint is based on the Severe Impairment Battery scale, a well-validated assessment used extensively in severe Alzheimer's disease drug trials. Secondary efficacy endpoints include Activities of Daily Living, Neuropsychiatric Inventory and Mini-Mental State Exam. As a result of this amendment, the Company expects to report top line data late in the first quarter or early in the second quarter of 2017.
Neurotrope Announces Changes to the Board of Directors and Management
PR Newswire - Fri Aug 05, 7:30AM CDT
Neurotrope, Inc. (OTCBB: NTRP) (the "Company"
, focused on developing drugs to treat neurological diseases including Alzheimer's disease, today announced it has reached a settlement agreement with Iroquois Master Fund Ltd. and certain of its affiliates (collectively "Iroquois", with regard to a proposed consent solicitation by Iroquois. Neurotrope announces that a new study published in the Journal of Biological Chemistry shows that Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
PR Newswire - Thu Jun 23, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that a study published in the Journal of Biological Chemistry shows that its lead Alzheimer's drug, Bryostatin, licensed from the Blanchette Rockefeller Neurosciences Institute (BRNI), increases the levels of the synaptic scaffolding protein PSD-95, and induces the movement of phosphorylated PSD-95 to the neuronal membranes. The study, conducted within the BRNI basic research programs, showed that Bryostatin induced activation of PKC epsilon increased synaptic number, pre-synaptic vesicle density, and clusters of PSD-95. It is known that either AB or tau, both toxic proteins in Alzheimer's disease brains, can induce reduction of PSD-95 in excitatory synapses in hippocampus. Furthermore, this PSD-95 reduction continues to occur as the Alzheimer's pathologies advance. A Phase 2b clinical trial funded by Neurotrope Bioscience, Inc., Neurotrope, Inc.'s wholly-owned subsidiary, is underway to test the efficacy of Bryostatin for the treatment of the causes and progression of Alzheimer's disease.
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
PR Newswire - Tue Jun 21, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP): today announced that Paula T. Trzepacz, M.D., has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President and Chief Medical Officer.
Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease
PR Newswire - Mon Jun 13, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP): Dr. Daniel Alkon, Chief Scientific Officer of Neurotrope, discussed "Modulation of PKC Epsilon as a Therapeutic Strategy" as a potential treatment for both Fragile X mental retardation and Alzheimer's disease at the Autism-Related Disorders Gordon Conference.
Neurotrope Enters Into Research Collaboration With the International Rett Syndrome Foundation / Rettsyndrome.org
PR Newswire - Thu May 19, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer's disease (AD), is pleased to announce that it has entered into a research collaboration with the International Rett Syndrome Foundation, DBA: Rettsyndrome.org, to explore the potential of Bryostatin for the treatment of Rett syndrome.
Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model
PR Newswire - Tue Mar 08, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced that its lead Alzheimer's drug Bryostatin improved disease symptoms and restored normal synaptic networks in a young transgenic animal model of Fragile X Syndrome (FXS), a common genetic cause of mental retardation and autism. The study led by scientists at the Blanchette Rockefeller Neuroscience Institute (BRNI) demonstrated that chronic treatment with bryostatin-1 rescues young fragile X mice (corresponding to 15 - 16 year old children) from the disorder phenotypes, including reversal of most FXS abnormalities of 1) hippocampal brain-derived neurotrophic factor (BDNF) expression, 2) the synaptic anchoring protein, PSD-95, levels, 3) transformation of immature dendritic synapses to fully mature, developed synapses, 4) sub-cellular densities of the presynaptic and postsynaptic membranes, and 5) spatial learning and memory. These results were long lasting and confirmed by electron microscopy. While other attempts at Fragile X therapeutics have focused on reduced mGluR5 receptor levels, the Bryostatin efficacy for treating Fragile X did not require changes of mGluR5 and were even more dramatic than those of a late-onset treatment in adult Fragile X mice. As a result of the mutation of the FMR1 gene, the Fragile X mental retardation protein (FMRP) is not produced. It is known that this protein is abundant in the neurons of the hippocampus and cerebellum of non-affected individuals, but it is not yet fully understood why the absence of FMRP results in the phenotype of Fragile X. We have found that chronic activation of PKC in the hippocampus by Bryostatin can rescue synapses and spatial cognition, as well as other FXS phenotypes. This rescue in Fragile X mice is remarkably similar to the rescue of synapses, spatial cognition, and other Alzheimer's disease (AD) phenotypes in AD transgenic mice. The new Fragile X study in late brain development is entitled "Rescue of Synaptic Phenotypes and Special Memory in Young Fragile X Mice," was authored by Miao-Kun Sun, Jarin Hongpaisan, and Dr. Daniel L. Alkon, and is published, in the Fast Forward edition of the Journal of Pharmacology and Experimental Therapeutics, dated March 3, 2016.
Neurotrope CSO to Participate in Alzheimer's Panel at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 04, 10:19AM CST
Neurotrope, Inc. (NTRP) today announced that its Chief Scientific Officer, Dr. Daniel Alkon, has been invited to present on a panel focused on new directions and progress of Alzheimer's disease research at the 18 Annual BIO CEO & Investor Conference, being held February 8-9, 2016 at the Waldorf Astoria Hotel in New York, New York.
Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer's Disease
GlobeNewswire - Wed Feb 03, 7:40AM CST
Neurotrope, Inc. (OTCBB:NTRP) today announced that it has held an Investigators Meeting in conjunction with its recently initiated Phase 2b trial for lead compound, Bryostatin-1 for the treatment of Alzheimer's disease. The meeting, held January 28-29, 2016 in Orlando, Florida, brought together more than 150 healthcare clinical professionals from 30 sites across the United States to discuss the goals for the study, in addition to providing the in-depth training necessary for the trial.
Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer's Disease
GlobeNewswire - Thu Jan 07, 7:30AM CST
Neurotrope, Inc. (OTCBB:NTRP) today announced the initiation of a Phase 2b clinical trial of lead candidate Bryostatin 1 for the treatment of Alzheimer's Disease.
Neurotrope, Inc. Announces $15.3 million Private Placement
PR Newswire - Mon Nov 16, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced that it has entered into definitive agreements to sell its securities in a private placement. The securities purchase agreement provides for the sale of units to investors for $0.60 per unit with each unit consisting of one one-hundredth share of Series B Preferred Stock convertible into one share of common stock and one of each of the following warrants:
Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease
PR Newswire - Wed Jun 24, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its operating wholly-owned subsidiary ("Neurotrope"
, will conduct a preclinical study, in collaboration with a leading research institution, to examine the effect of bryostatin in Niemann-Pick type C (NPC) mice. The study is being funded by several family foundations under the auspices of Support Of Accelerated Research for NPC Disease ("SOAR-NPC". Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C
PR Newswire - Fri Jun 12, 7:30AM CDT
Neurotrope Bioscience, Inc. (Neurotrope or the Company), the operating subsidiary of Neurotrope, Inc. (OTCQB: NTRP) today announced the Company will present the findings of in vitro studies of bryostatin's effects on Niemann Pick Type C1 cells (NPC1 cells) at the annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C research to be held on June 11 -13, 2015 at the University of Notre Dame. The Company's presentation will take place on Friday, June 12, at 2:30 pm Eastern time.
Neurotrope Joins National Organization for Rare Disorders (NORD) Corporate Council
PR Newswire - Thu Apr 23, 7:00AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that, based upon its work in orphan drug indications, it has been invited to join the National Organization for Rare Disorders (NORD) as a member of the NORD Corporate Council. NORD is a leading independent, non-profit organization committed to the identification, treatment, and cure of rare disorders.
Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research
PR Newswire - Mon Apr 20, 7:35AM CDT
In the search for neuroscience drug discovery treatments, Alzheimer's disease and specifically autism drug candidates, a few viable therapeutic approaches have come from research on neurological conditions such as fragile X syndrome. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), CytRx Corporation (NASDAQ: CYTR), Trovagene, Inc., (NASDAQ: TROV), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Abbot Laboratories (NYSE: ABT) & Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).
ABT: 45.15 (+0.11), LXRX: 16.24 (+0.29), TROV: 5.71 (+0.10), CYTR: 0.58 (+0.01), BMY: 60.03 (-0.60), ARNA: 1.71 (+0.04)
Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies
PR Newswire - Mon Apr 20, 6:55AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that eurotrope BioScience, Inc., its wholly-owned operating subsidiary, has received a grant from the FRAXA Research Foundation, Inc. ("FRAXA"
to fund a pre-clinical Fragile X Syndrome ("FXS" behavior study for its lead proprietary drug candidate, bryostatin, at FRAXA's purpose built laboratory located at the University of Chile in Santiago, Chile. Leading Biotech Companies Seek Biologic Treatments for Rare Diseases Utilizing Viable Therapeutic Approach - Company Receives FDA Orphan Drug Designation for Bryostatin
PR Newswire - Thu Apr 09, 7:35AM CDT
According to a recent article published on the Wall Street Journal, the debate over prescription drug pricing has grown increasingly contentious, particularly as drug makers issue more new medicines with high price tags. But despite the tumult, the cost for orphan drugs - medicines that are designated by the FDA to treat a rare disease and may cost as much as $400,000 annually - is apparently not fazing some insurers. Billions of dollars a year are being earmarked for new clinical studies and trials for the treatment of neurodevelopmental disorders as leading biotech companies race to identify treatments for genetic, cognitive, and neural levels for autism disorders. Biotech Companies in focus today are Neurotrope, Inc. (OTC: NTRP), Alkermes plc (NASDAQ: ALKS), Regulus Therapeutics Inc. (NASDAQ: RGLS), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Gilead Sciences Inc. (NASDAQ: GILD) and Abbot Laboratories (NYSE: ABT).
ABT: 45.15 (+0.11), INO: 8.88 (-0.07), GILD: 79.65 (-0.01), RGLS: 3.64 (+0.09), ALKS: 48.03 (+1.36)
Research & Clinical Trials for Prevention of Neurodegeneration Search for Viable Therapeutic Approach for the Treatment of Severe Alzheimer's Disease
PR Newswire - Mon Apr 06, 7:35AM CDT
The latest medical research and trials aimed to identify prevention of illnesses, particularly ones related to aging and lifestyle, including Alzheimer's disease, cancer, heart disease and other serious illnesses use innovative and novel approaches to ultimately develop the licensed technology for many types of cognitive dysfunctions. Biotech Companies in focus today: Neurotrope, Inc. (OTC: NTRP), Capnia, Inc. (NASDAQ: CAPN), Arena Pharmaceuticals, Inc., (NASDAQ: ARNA), Orexigen Therapeutics, Inc., (NASDAQ: OREX) & Inovio Pharmaceuticals, Inc., (NASDAQ: INO).
INO: 8.88 (-0.07), OREX: 4.34 (+0.16), CAPNU: (), ARNA: 1.71 (+0.04), CAPN: 0.90 (-0.05)
